Aldesleukin by Iovance Biotherapeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval

Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD).

AMA Delegates Dive Into Water Bead Injuries; Patients’ ‘Scanxiety’ Over Test Results

Members of the American Medical Association (AMA) House of Delegates (HOD) Saturday attacked dozens of worsening obstacles they blamed for making safe patient care increasingly

November 11, 2024

Bristol Myers pays $80M to license another Prothena neuroscience candidate

Bristol Myers Squibb is shelling out $80 million to Prothena for an exclusive global license for an early-stage neurodegenerative candidate, as the pharma giant continues

May 30, 2024

Another major pharma company departs BIO

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well. UCB, headquartered in

January 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.